Reviewing Ligand Pharmaceuticals Incorporated (LGND)’s and Cyanotech Corporation (NASDAQ:CYAN)’s results

This is therefore a comparing of the analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Cyanotech Corporation (NASDAQ:CYAN). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ligand Pharmaceuticals Incorporated 251.45M 9.97 143.32M 8.82 16.84
Cyanotech Corporation 31.35M 0.57 2.36M -0.21 0.00

Table 1 demonstrates Ligand Pharmaceuticals Incorporated and Cyanotech Corporation’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has Ligand Pharmaceuticals Incorporated and Cyanotech Corporation’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals Incorporated 57.00% 32.3% 13.3%
Cyanotech Corporation -7.53% -13.5% -7.9%

Risk & Volatility

Ligand Pharmaceuticals Incorporated’s current beta is 1.55 and it happens to be 55.00% more volatile than Standard & Poor’s 500. Cyanotech Corporation on the other hand, has 0.67 beta which makes it 33.00% less volatile compared to Standard & Poor’s 500.

Liquidity

Ligand Pharmaceuticals Incorporated’s Current Ratio is 2.2 while its Quick Ratio is 2.2. On the competitive side is, Cyanotech Corporation which has a 1.8 Current Ratio and a 0.4 Quick Ratio. Ligand Pharmaceuticals Incorporated is better positioned to pay off short and long-term obligations compared to Cyanotech Corporation.

Analyst Ratings

In next table is given Ligand Pharmaceuticals Incorporated and Cyanotech Corporation’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ligand Pharmaceuticals Incorporated 0 1 1 2.50
Cyanotech Corporation 0 0 0 0.00

Ligand Pharmaceuticals Incorporated’s upside potential is 122.94% at a $263 consensus price target.

Institutional and Insider Ownership

Ligand Pharmaceuticals Incorporated and Cyanotech Corporation has shares owned by institutional investors as follows: 0% and 13.8%. About 2.1% of Ligand Pharmaceuticals Incorporated’s share are owned by insiders. Comparatively, insiders own roughly 19.1% of Cyanotech Corporation’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ligand Pharmaceuticals Incorporated -5.8% -8.81% -42.02% -22.84% 12.91% 8.54%
Cyanotech Corporation -5.56% 6.06% -3.37% -12.73% -17.93% -11.82%

For the past year Ligand Pharmaceuticals Incorporated had bullish trend while Cyanotech Corporation had bearish trend.

Summary

Ligand Pharmaceuticals Incorporated beats on 12 of the 12 factors Cyanotech Corporation.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.

Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition market worldwide. The companyÂ’s products include Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids; and Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the bodyÂ’s natural inflammatory response, enhance skin, and support eye and joint health. Cyanotech Corporation sells its products in bulk quantities to manufacturers, formulators, and distributors in the health foods and nutritional supplements markets; and as packaged consumer products to distributors, retailers, and direct consumers. The company also sells its products online at nutrex-hawaii.com. Cyanotech Corporation was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.